SEC Form 4 · accession 0001209191-17-051252
bluebird bio, Inc. · BLUE
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Jeffrey T. Walsh
Officer — Chief Financial · Other
Period of report
Aug 31, 2017
Accepted (ET)
Sep 5, 2017 · 4:02 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001293971
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | Aug 31, 2017 | M | 12,000 | $5.5004 | A | 39,305 | D | |
| Common StockF2 | Aug 31, 2017 | S | 12,000 | $125.0076 | D | 27,305 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (right to buy)F3 | $5.5004 | Aug 31, 2017 | M | 12,000 | D | — | Jan 16, 2023 | Common Stock | 12,000 | 72,385 | D |
Explanation of responses
- F1The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 23, 2016.
- F2The range of prices for the transaction reported on this line was $125.00 to $125.15. The average weighted price was $125.0076. The reporting person will provide, upon request by the SEC, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price.
- F3This option to purchase shares of our common stock granted on January 16, 2013 with performance-based vesting criteria that were met as of January 1, 2013. The shares underlying these options vested as follows: 25% vested on January 1, 2014, with the remainder of the shares vesting in equal monthly installments over the following three years.